JP2022554353A5 - - Google Patents

Info

Publication number
JP2022554353A5
JP2022554353A5 JP2022525990A JP2022525990A JP2022554353A5 JP 2022554353 A5 JP2022554353 A5 JP 2022554353A5 JP 2022525990 A JP2022525990 A JP 2022525990A JP 2022525990 A JP2022525990 A JP 2022525990A JP 2022554353 A5 JP2022554353 A5 JP 2022554353A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
administration
product according
cells
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554353A (ja
JP7837864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059550 external-priority patent/WO2021092498A1/en
Publication of JP2022554353A publication Critical patent/JP2022554353A/ja
Publication of JP2022554353A5 publication Critical patent/JP2022554353A5/ja
Application granted granted Critical
Publication of JP7837864B2 publication Critical patent/JP7837864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525990A 2019-11-07 2020-11-06 T細胞療法と(s)-3-[4-(4-モルホリン-4-イルメチル-ベンジルオキシ)-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル]-ピペリジン-2,6-ジオンとの併用 Active JP7837864B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962932500P 2019-11-07 2019-11-07
US62/932,500 2019-11-07
US202063016977P 2020-04-28 2020-04-28
US63/016,977 2020-04-28
PCT/US2020/059550 WO2021092498A1 (en) 2019-11-07 2020-11-06 Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione

Publications (3)

Publication Number Publication Date
JP2022554353A JP2022554353A (ja) 2022-12-28
JP2022554353A5 true JP2022554353A5 (https=) 2023-11-15
JP7837864B2 JP7837864B2 (ja) 2026-03-31

Family

ID=73699424

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525990A Active JP7837864B2 (ja) 2019-11-07 2020-11-06 T細胞療法と(s)-3-[4-(4-モルホリン-4-イルメチル-ベンジルオキシ)-1-オキソ-1,3-ジヒドロ-イソインドール-2-イル]-ピペリジン-2,6-ジオンとの併用

Country Status (10)

Country Link
US (1) US20220401483A1 (https=)
EP (1) EP4054623A1 (https=)
JP (1) JP7837864B2 (https=)
KR (1) KR20220122615A (https=)
CN (1) CN114980918A (https=)
AU (1) AU2020379043A1 (https=)
BR (1) BR112022007548A2 (https=)
IL (1) IL292667B1 (https=)
MX (1) MX2022005524A (https=)
WO (1) WO2021092498A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
US20230165872A1 (en) * 2020-04-28 2023-06-01 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
AU2013299627C1 (en) 2012-08-09 2018-05-31 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
ES2885769T3 (es) * 2012-08-09 2021-12-15 Celgene Corp Una forma sólida de clorhidrato de (s)-3-(4-((4-morpholinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
JP7062640B2 (ja) 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗cd19抗体に対する抗イディオタイプ抗体
CN118948892A (zh) 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
AU2018275894B2 (en) * 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation

Similar Documents

Publication Publication Date Title
AU2018203924B2 (en) Toxicity management for anti-tumor activity of cars
AU2017302668B2 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
JP2023519099A5 (https=)
EP3407911B1 (en) Methods and pharmaceutical composition for the treatment of cancer
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
JP2022512917A5 (https=)
JP2022513685A5 (https=)
JP2021512107A5 (https=)
JP2021523122A5 (https=)
JP2025134707A5 (https=)
JP2023524430A5 (https=)
JP2023522857A5 (https=)
JP2024540275A5 (https=)
JP2022513062A5 (https=)
JP2025175307A (ja) 逐次抗cd19治療
JP2022554353A5 (https=)
JP2024513054A5 (https=)
JP2023513434A5 (https=)
JP2024514163A5 (https=)
JP2023524068A5 (https=)
JP2024540320A5 (https=)
WO2025120866A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
WO2025121445A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2